Microbot Medical (Microbot Medical) Cash, Cash Equivalents, Marketable Securities : $6.35 Mil (As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Microbot Medical Cash, Cash Equivalents, Marketable Securities?

Microbot Medical's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($8.15 Mil) to Dec. 2023 ($6.39 Mil) but then stayed the same from Dec. 2023 ($6.39 Mil) to Mar. 2024 ($6.35 Mil).

Microbot Medical's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($15.49 Mil) to Dec. 2022 ($8.21 Mil) and declined from Dec. 2022 ($8.21 Mil) to Dec. 2023 ($6.39 Mil).

Microbot Medical Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Microbot Medical's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbot Medical Cash, Cash Equivalents, Marketable Securities Chart

Microbot Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

31.29

24.65

15.49

8.21

6.39

Microbot Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															5.06	9.92	8.15	6.39	6.35

Microbot Medical Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Microbot Medical (NAS:MBOT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Microbot Medical Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Microbot Medical's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Microbot Medical (Microbot Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Microbot Medical Inc (NAS:MBOT) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

CY9D:Germany

Address

25 Recreation Park Drive, Unit 108, Hingham, MA, USA, 02043

Website

https://microbotmedical.com

Microbot Medical Inc is a pre-clinical medical device company. It specializes in developing next-generation micro-robotic medical technologies that can change the future of medicine. Their vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures and offer physicians and their patients less invasive and more precise solutions. The company's innovative platforms LIBERTY and Self-Cleaning Shunt (SCS) are in one of the fastest-growing segments in healthcare. The group continuously develops its technology with the goal to improve surgical outcomes worldwide. The firm presently holds domestic and global patents that strengthen its product portfolio and create barriers of entry.

Executives

Rachel Vaknin	officer: Chief Financial Officer	DROR 3/10, ZICHRON YAAKOV L3 3090216
Simon Sharon	officer: General Manager & CTO	8 HAMADA STREET, ZICHRON YAACOV L3 3090708
Yoseph Bornstein	director, 10 percent owner	16 IRUS STREET, ROSH HA'AYIN L3 4858022
Tal Baruch Wenderow	director	1149, BEACON STREET, NEWTON MA 02461
Eyal Morag	officer: Chief Medical Officer	BONEY HAEAR 3 STREET, APT #13, TEL AVIV L3 6937303
Aileen Ptucha Stockburger	director	26 WELLINGTON CT, BELLE MEADE NJ 08502
Harel Gadot	director, 10 percent owner, officer: Chairman and CEO	5 VILLAGE LANE, HINGHAM MA 02043
Joseph Mona	10 percent owner	808 HAMPTON ST, COLUMBIA SC 29201
Prattipati Laxminarain	director	3 HEWINS FARM ROAD, WELLESLEY MA 02481
Yoav Zvi Waizer	director	8 HAVERED STREET, RAANANA L3 4352308
Moshe Shoham	director	22 BEDOLACH STREET, HOSHAYA L3 1791500
Leon Lewkowicz	10 percent owner	GORDON STREET 10, APARTMENT 7, TEL-AVIV L3 63458
Martin J. Madden	director	C/O MICROBOT MEDICAL INC., 175 DERBY STREET 27/1, HINGHAM MA 02043
Yehezkel Himelfarb	officer: General Manager & COO	32 BEN YOSEF STREET, TEL-AVIV L3 6912530
Sandra Berkson	10 percent owner	C/O SABER HOLDING GMBH, WEIN KRUMMBAUMGASSE C4 1020